ClinicalTrials.gg
RecruitingNCT05749822Updated Jan 8, 2026

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

A Phase 2/3 interventional study of Fenofibrate 200mg and Placebo in Primary Biliary Cholangitis, sponsored by Xijing Hospital of Digestive Diseases. Recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Xijing Hospital of Digestive Diseases · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary — 7 open to participants now, 9 under way, 8 of them phase 3. Fenofibrate · Liver Cirrhosis, Biliary.

Planned enrollment
8th of 13
104 · median 117
Started
2023
with 2 others
Phase 2/3
3 of 13
2 open now
Registered
6th of 13
by date
Lead sponsor
9 of 13
Xijing Hospital of Digestive Diseases

Among the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, this one is the 8th largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 2/3, and was the 6th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

7 of the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About fenofibrate

Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, or all of them as a file.
02

Study summary

The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC).

Read the detailed description

This is a multi-center, randomized, placebo-controlled, parallel-group study that aims to assess the efficacy and safety of fenofibrate in patients with compensated cirrhosis PBC who had an inadequate biochemical response to UDCA. Fenofibrate or placebo 200 mg will be daily administered in combination with UDCA 13-15 mg/kg/d for 12 months.

03

Conditions studied

  • Primary Biliary Cholangitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have provided written
  • Age 18-75 years;
  • 17-28 kg/m2
  • Male or female with a diagnosis of PBC, by at least two of the following criteria:

    1. History of AP above for at least six months;
    2. Positive AMA titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies;
    3. Documented liver result consistent with PBC.
  • Diagnosis of compensated cirrhosis, as demonstrated by the presence of ≥ 1 of the following 4 diagnostic factor

    1. The histology was consistent with the diagnosis of liver cirrhosi;
    2. Endoscopy shows esophageal and gastric varices or ectopic varices of digestive tract, excluding non cirrhotic portal hypertension;
    3. Ultrasound or CT and other imaging examinations indicate the characteristics of liver cirrhosis or portal hypertension, such as splenomegaly, portal vein ≥ 1.3 cm, or liver stiffness measured by transient elastography>16.9 kPa;
    4. Abnormal laboratory inspection indicators (2 out of 4): 1) \< 100 × 109/L, and no other reason can be explained; 2) Serum albumin\<35 g/L, excluding malnutrition or kidney disease and other causes; 3) > 1.3 or PT prolongation (stop thrombolytic or anticoagulant drugs for more than 7 days); 4) /PLT (APRI)>2)
  • Incomplete response to UDCA defined by ALP > 1.67 x ULN
  • Taking UDCA for at least 6 months (stable dose for ≥ 3 months) prior to Day 0

Exclusion criteria

Exclusion Criteria:

  • History or presence of other concomitant liver diseases.
  • or AST > 5×, > 3×ULN.
  • If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating.
  • Allergic to fenofibrate or ursodeoxycholic acid.
  • Taking hepatotoxic drugs (e.g., dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than 2 weeks within 6 months, and long-term hormonal users.
  • Recurrent variceal bleeding, poorly controlled hepatic encephalopathy or ascites.
  • Patients with a history of severe cardiac, cerebrovascular, renal, respiratory disease or functional failure, and psychiatric disorders (including those due to alcohol and drug abuse).
  • Creatinine >1.5×ULN and \<60 ml/min.
  • Currently using statins (such as pravastatin, fluvastatin, and simvastatin), other fibrates (such as gemfibrozil and bezafibrate), and drugs structurally similar to fenofibrate (like ketoprofen).
  • Planned to receive an organ transplant or an organ transplant recipient.
  • Needing Liver transplantation within 1 year according to the Mayo Rick score.
  • Any other condition(s) that would compromise the safety of the subject or compromise
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Placebo comparator
    Placebo-UDCA

    1 tablet/ day and UDCA 13-15mg/kg/day for 12 months

    Drug: Placebo · Drug: UDCA

  • Experimental
    Fenofibrate-UDCA

    Fenofibrate 200 mg/day and UDCA 13-15mg/kg/day for 12 months

    Drug: Fenofibrate 200mg · Drug: UDCA

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients with biochemical response

    The normalisation of Alkaline Phosphatase

    Time frame: 48 weeks

Secondary outcomes

  1. Percentage of patients having biochemical response

    The normalisation of Alkaline Phosphatase at 4, 12, 24, and 36 weeks.

    Time frame: 4, 12, 24 and 36weeks

  2. Assessment of the pruritus and fatigue

    Change From Baseline in Fatigue and Pruritus as Assessed by Visual Analogue Scale (VAS) Total Score for Fatigue and Pruritus. (0-10, higher scires mean a worse outcome)

    Time frame: 4, 12, 24, 36, and 48 weeks

  3. Percentage of patients having biological or clinical adverse events

    Increase of creatinine

    Time frame: 4, 12, 24, 36, and 48 weeks

  4. Percentage of patients having biological or clinical adverse events

    Increase Blood urea nitrogen

    Time frame: 4, 12, 24, 36, and 48 weeks

  5. Percentage of patients having biological or clinical adverse events

    Increase of creatine kinase

    Time frame: 4, 12, 24, 36, and 48 weeks

  6. Percentage of patients having biological or clinical adverse events

    Increase ALT and AST.

    Time frame: 4, 12, 24, 36, and 48 weeks

  7. Survival without transplantation and hepatic impairment

    Occurrence of ascites, variceal bleeding, hepatic encephalopathy, liver-transplantation, or death.

    Time frame: 48 weeks

07

Study locations

11 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2022
First posted
Mar 1, 2023
StartActual
Feb 17, 2023
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05749822
Lead sponsor
Xijing Hospital of Digestive Diseases
Responsible party
Han Ying (Professor, Xijing Hospital of Digestive Diseases) — Principal investigator
First posted
Mar 1, 2023
Start date
Feb 17, 2023
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 8, 2026

Study contacts

Yulong Shang
Contact
shangyl870222@163.com
+86-29-84771539
Ying Han
Contact
hanying1@fmmu.edu.cn
+86-29-84771539
Ying Han
principal investigator · Xijing Hospital, Air Force Military Medical Universit

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenofibrate

Start the discussion